• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by GoHealth Inc. (Amendment)

    5/19/23 6:04:02 AM ET
    $GOCO
    Specialty Insurers
    Finance
    Get the next $GOCO alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

     

    GoHealth, Inc.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    38046W105

    (CUSIP Number)

     

    Clinton P. Jones

    214 West Huron St.

    Chicago, IL 60654

    (312) 386-8200

     

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

     

    With copies to:

     

    Patrick Croke

    Croke Fairchild Duarte & Beres LLC

    180 N LaSalle Street, Ste. 3400

    Chicago, IL 60601

    (312) 650-8650

     

    May 18, 2023

    (Date of Event Which Requires Filing of This Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), Rule 13d-1(f) or Rule 13d-1(g), check the following box. ☐

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

     

       
    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     

     

     

     

    CUSIP No. 38046W105 13D Page 2 of 9 pages

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

    1

    Names of Reporting Persons

     

    NVX Holdings, Inc.

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐      (b) ☒

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

    OO

    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    6,232,352

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    6,232,352

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,232,352

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    40.8%

    14

    Type of Reporting Person

     

    CO

                  

     

     

     

    CUSIP No. 38046W105 13D Page 3 of 9 pages

     

    1

    Names of Reporting Persons

     

    Brandon M. Cruz

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐      (b) ☒

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

      OO
    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    194,319
    8

    Shared Voting Power

     

    6,247,139

    9

     

    Sole Dispositive Power

     

    194,319

     

    10

     

    Shared Dispositive Power

     

    6,247,139

     
    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,441,458

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    42.3%

    14

    Type of Reporting Person

     

    IN

               

     

     

     

    CUSIP No. 38046W105 13D Page 4 of 9 pages

     

    1

    Names of Reporting Persons

     

    Clinton P. Jones

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐     (b) ☒

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

    OO

    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     

    6

    Citizenship or Place of Organization

     

    United States

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    194,319

    8

    Shared Voting Power

     

    6,247,139

    9

    Sole Dispositive Power

     

    194,319

    10

    Shared Dispositive Power

     

    6,247,139

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    6,441,458

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    42.3%

    14

    Type of Reporting Person

     

    IN

                 

     

     

     

    CUSIP No. 38046W105 13D Page 5 of 9 pages

     

    1

    Names of Reporting Persons

     

    BCCJ, LLC

    2

    Check the Appropriate Box if a Member of a Group (See Instructions)

     

    (a) ☐     (b) ☒

    3

    SEC Use Only

     

    4

    Source of Funds (See Instructions)

     

    OO

    5

    Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

    ☐

    6

    Citizenship or Place of Organization

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    7

    Sole Voting Power

     

    0

    8

    Shared Voting Power

     

    14,787

    9

    Sole Dispositive Power

     

    0

    10

    Shared Dispositive Power

     

    14,787

    11

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

    14,787

    12

    Check if the Aggregate Amount in Row (11) Excludes Certain Shares

     

    ☐

    13

    Percent of Class Represented by Amount in Row (11)

     

    0.2%

    14

    Type of Reporting Person

     

    OO (Limited Liability Company)

                   

     

     

     

    CUSIP No. 38046W105 13D Page 6 of 9 pages

     

    Explanatory Note

     

    This Amendment No. 1 to Schedule 13D (“Amendment No. 1”) amends and supplements the Schedule 13D originally filed with the United States Securities and Exchange Commission on November 25, 2022 (the “Schedule 13D”), relating to the shares of Class A Common Stock, par value $0.0001 per share (the “Class A Common Stock”), of GoHealth, Inc., a Delaware corporation (the “Issuer”). Capitalized terms used herein without definition shall have the meanings set forth in the Schedule 13D.

     

    Item 4. Purpose of Transaction.

     

    Item 4 of the Schedule 13D is hereby amended and supplemented as follows:

     

    On the evening of May 18, 2023, the Reporting Persons and CCP III Cayman GP Ltd., CB Blizzard Holdings C, L.P., Centerbridge Associates III, L.P., CCP III AIV VII Holdings, L.P., CB Blizzard Co-Invest Holdings, L.P., CB Blizzard Lower Holdings GP A, LLC, CB Blizzard Lower Holdings A, L.P., Blizzard Aggregator, LLC, CB Blizzard Lower Holdings GP B, LLC, CB Blizzard Lower Holdings B, L.P., and Jeffrey H. Aronson (collectively, the “CB Stockholders”) delivered a non-binding proposal (the “Proposal”) to the Board of Directors (the “Board”) of the Issuer offering to acquire all of the outstanding shares of Class A Common Stock and LLC Interests that the Reporting Persons and the CB Stockholders do not already own for a price per share or LLC Interest equal to $20.00 (the “Proposed Transaction”). The Proposal is non-binding, and the Reporting Persons and the CB Stockholders have not proposed any specific structure for the Proposed Transaction nor have they received any feedback from the Issuer. The foregoing description of the Proposal does not purport to be complete and is qualified in its entirety by reference to the full text of the Proposal, which is filed herewith as Exhibit 4 and incorporated herein by reference.

     

    The Proposal is non-binding in nature and does not obligate in any way the Reporting Persons or the Issuer to negotiate or enter into definitive documentation with respect to a transaction or otherwise complete the Proposed Transaction, and a binding commitment with respect to the Proposed Transaction will result only from the execution and delivery of definitive documentation. Any definitive documentation entered into in connection with the Proposed Transaction is likely to be subject to customary closing conditions. The Reporting Persons make no assurances that the Proposed Transaction contemplated by the Proposal will be consummated, even if the Issuer accepts the Proposal, and make no assurance as to the terms of any such transaction if one were to be consummated.

     

    Neither the Proposal nor this Schedule 13D is meant to be, nor should be construed as, an offer to buy or the solicitation of an offer to sell any of the Issuer’s securities.

     

    If the Proposed Transaction is consummated, one or more of the transactions, events or actions specified in clauses (a) through (j) of Item 4 of Schedule 13D may result, including, without limitation, an acquisition of additional securities of the Issuer, an extraordinary corporate transaction (such as a merger) involving the Issuer, other material changes in the Issuer’s business or corporate structure, and the shares of the Class A Common Stock would become eligible for termination of registration pursuant to Section 12(g)(4) of the Securities Act and would be delisted from the Nasdaq Stock Market.

     

    The Reporting Persons intend to continue to engage in discussions with, among others, management, the Board, stockholders (including the CB Stockholders) and other stakeholders of the Issuer, and/or third parties, including potential acquirers, service providers and debt and equity financing sources, and other relevant parties and may take other actions concerning any extraordinary corporate transaction (including but not limited to a merger, reorganization or liquidation) or the business, operations, assets, strategy, future plans, prospects, corporate structure, Board composition, management, capitalization, dividend policy, charter, bylaws, corporate documents, agreements, de-listing or de-registration of the Issuer, which discussions may include proposing or considering proposals and counterproposals. The Reporting Persons reserve the right to modify or withdraw the Proposal at any time. While the Proposal remains under consideration by the Issuer, the Reporting Persons and their affiliates expect to respond to inquiries from, and negotiate the terms of the Proposal with, the Issuer and its representatives. The Reporting Persons do not intend to update additional disclosures regarding the Proposal until a definitive agreement has been reached with respect to the Proposed Transaction, or unless disclosure is otherwise required under applicable U.S. securities laws.

     

     

     

     

    CUSIP No. 38046W105 13D Page 7 of 9 pages

     

    The Reporting Persons intend to regularly review their investment in the Issuer on a continuing basis and may from time to time and at any time in the future depending on various factors, including, without limitation, the outcome of any discussions referenced in this Schedule 13D, as may be amended from time to time, and any limitations imposed by the Issuer’s financial position and strategic direction, actions taken by the Board, price levels of the Issuer’s securities, other investment opportunities available to the Reporting Persons, conditions in the securities market and general economic and industry conditions, take such actions with respect to the investment in the Issuer as they deem appropriate. These actions may include, (i) acquiring additional shares of Class A Common Stock and/or other equity, debt, notes, other securities, or derivative or other instruments that are based upon or relate to the value of securities of the Issuer (collectively, “Securities”) in the open market or otherwise; (ii) disposing of any or all of their Securities in the open market or otherwise; (iii) engaging in any hedging or similar transactions with respect to the Securities; or (iv) proposing or considering one or more of the actions described in subsections (a) through (j) of Item 4 of Schedule 13D.

     

    Although the foregoing reflects activities presently contemplated by the Reporting Persons, the foregoing is subject to change at any time, and the Reporting Persons reserve their right to change their plans and intentions with respect to the Issuer, including in connection with any of the actions discussed in this Item 4, including, among others, any terms related to the Proposal. Any action taken by the Reporting Persons may be effected at any time and from time to time, subject to any applicable limitations imposed by any applicable laws.

     

    Item 5. Interest in Securities of the Issuer.

     

    Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows:

     

    (a) – (b)

     

    The following sets forth, as of the date of this Schedule 13D, the aggregate number of shares of Class A Common Stock and percentage of Class A Common Stock beneficially owned by each of the Reporting Persons, as well as the number of shares of Class A Common Stock as to which each Reporting Person has the sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition of, or shared power to dispose or to direct the disposition of, as of the date hereof, based on 9,041,091 shares of Class A Common Stock outstanding as of May 1, 2023, as provided by the Issuer in the Quarterly Report on Form 10-Q filed by the Issuer on May 9, 2023, plus, as applicable, 6,178,532 and 2,921 shares of Class A Common Stock underlying the LLC Interests held of record by NVX and BCCJ, respectively:

     

    Reporting Person 

    Amount beneficially owned

      

    Percent

    of class

      

    Sole power to vote or to direct the vote

      

    Shared power to vote or to direct the vote

      

    Sole power to dispose or to direct the disposition

      

    Shared power to dispose or to direct the disposition

     
    NVX Holdings, Inc.   6,232,352    40.8%   0    6,232,352    0    6,232,352 
    Brandon M. Cruz   6,441,458    42.3%   194,319    6,247,139    194,319    6,247,139 
    Clinton P. Jones   6,441,458    42.3%   194,319    6,247,139    194,319    6,247,139 
    BCCJ, LLC   14,787    0.2%   0    14,787    0    14,787 

     

    NVX is the record holder of 53,820 shares of Class A Common Stock and 6,178,532 LLC Interests. BCCJ is the record holder of 11,866 shares of Class A Common Stock and 2,921 LLC Interests. Each of Messrs. Jones and Cruz is the record holder of 4,967 shares of Class A Common Stock.

     

    Messrs. Jones and Cruz are the Chief Executive Officer and President of NVX, respectively, and are members of the Board of Managers of BCCJ. As a result, each of Messrs. Jones and Cruz may be deemed to beneficially own the securities held by each of NVX and BCCJ.

     

    In addition, each of Messrs. Jones and Cruz may be deemed to beneficially own: (i) 5,016 shares of Class A Common Stock underlying stock options, (ii) 3,925 shares of Class A Common Stock underlying restricted stock units and (iii) 180,411 shares of Class A Common Stock underlying Blizzard Management Feeder LLC Interests, in each case that are currently vested or will vest within 60 days.

     

     

     

     

    CUSIP No. 38046W105 13D Page 8 of 9 pages

     

    By virtue of the agreements made pursuant to the Stockholders Agreement and the matters described in Item 4 above, the Reporting Persons and the CB Stockholders may constitute a “group” within the meaning of Section 13(d)(3) of the Securities Exchange Act of 1934 (the “Exchange Act”), which group may be deemed to collectively beneficially own 16,007,486 shares of Class A Common Stock of the Issuer, constituting approximately 77.6% of the 9,041,091 shares of the Class A Common Stock outstanding, plus the 5,386,178 shares of Class A Common Stock underlying the LLC Interests held of record by CB Blizzard B and the 6,181,453 shares of Class A Common Stock underlying the LLC Interests held of record by certain of the Reporting Persons, as calculated on the basis of Rule 13d-3 of the Exchange Act. However, the Reporting Persons expressly disclaim beneficial ownership of the 9,566,028 shares of Class A Common Stock (including 5,386,178 shares of Class A Common Stock underlying LLC Interests held of record by CB Blizzard B) beneficially owned by the CB Stockholders. The CB Stockholders have filed a separate Schedule 13D with respect to their interests in the Issuer and the Proposal.

     

    (c) During the past 60 days, the Reporting Persons have not effected any transactions with respect to the Class A Common Stock.

     

    (d) None.

     

    (e) Not applicable.

     

    Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer.

     

    Item 6 of the Schedule 13D is hereby supplemented as follows:

     

    The information set forth in Item 4 of this Schedule 13D is incorporated herein by reference.

     

    Item 7. Material to Be Filed as Exhibits.

     

    Item 7 of the Schedule 13D is hereby amended and supplemented by inserting the following exhibit:

     

    Exhibit

    Number

      

    Description

         
    1    Joint Filing Agreement.
         
    2    Stockholders Agreement, dated July 15, 2020, by and among GoHealth, Inc. and the persons and entities listed on the schedules attached thereto (incorporated by reference to Exhibit 10.4 to the Issuer’s Current Report on Form 8-K filed with the SEC on July 17, 2020).
         
    3    Registration Rights Agreement, dated July 15, 2020, by and among GoHealth, Inc. and each other person identified on the schedule of investors attached thereto (incorporated by reference to Exhibit 10.2 to the Issuer’s Current Report on Form 8-K filed with the SEC on July 17, 2020).
         
    4.  Proposal dated May 18, 2023.

     

     

     

     

    CUSIP No. 38046W105 13D Page 9 of 9 pages

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: May 19, 2023

     

      NVX Holdings, Inc.
         
      By: /s/ Brandon M. Cruz
      Name: Brandon M. Cruz
      Title: President
         
      Clinton P. Jones
         
      By: /s/ Clinton P. Jones
         
      Brandon M. Cruz
         
      By: /s/ Brandon M. Cruz
         
      BCCJ, LLC
         
      By: /s/ Brandon M. Cruz
      Name: Brandon M. Cruz
      Title: Manager

     

     

     

     

    Get the next $GOCO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $GOCO

    DatePrice TargetRatingAnalyst
    4/1/2022$1.50Underperform
    Credit Suisse
    3/3/2022$10.00 → $2.00Outperform → Sector Perform
    RBC Capital
    3/2/2022Buy → Hold
    Truist
    3/2/2022$2.00Buy → Hold
    Truist Securities
    1/7/2022$6.00 → $3.00Neutral → Underperform
    Credit Suisse
    1/5/2022$7.50 → $3.50Buy → Underperform
    B of A Securities
    11/15/2021$7.00 → $6.00Neutral
    Credit Suisse
    11/11/2021$13.00 → $5.50Equal-Weight
    Morgan Stanley
    More analyst ratings

    $GOCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Credit Suisse resumed coverage on GoHealth with a new price target

      Credit Suisse resumed coverage of GoHealth with a rating of Underperform and set a new price target of $1.50

      4/1/22 7:10:27 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth downgraded by RBC Capital with a new price target

      RBC Capital downgraded GoHealth from Outperform to Sector Perform and set a new price target of $2.00 from $10.00 previously

      3/3/22 4:36:13 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth downgraded by Truist

      Truist downgraded GoHealth from Buy to Hold

      3/2/22 7:31:46 AM ET
      $GOCO
      Specialty Insurers
      Finance

    $GOCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Legal Officer Burd Brad covered exercise/tax liability with 814 shares, decreasing direct ownership by 0.52% to 157,070 units (SEC Form 4)

      4 - GoHealth, Inc. (0001808220) (Issuer)

      5/7/25 2:04:59 PM ET
      $GOCO
      Specialty Insurers
      Finance
    • Chief Executive Officer Kotte Vijay covered exercise/tax liability with 24,612 shares, decreasing direct ownership by 2% to 1,221,491 units (SEC Form 4)

      4 - GoHealth, Inc. (0001808220) (Issuer)

      4/14/25 1:50:52 PM ET
      $GOCO
      Specialty Insurers
      Finance
    • Chief Executive Officer Kotte Vijay was granted 500,000 shares and covered exercise/tax liability with 221,500 shares, increasing direct ownership by 29% to 1,246,103 units (SEC Form 4)

      4 - GoHealth, Inc. (0001808220) (Issuer)

      4/7/25 4:40:00 PM ET
      $GOCO
      Specialty Insurers
      Finance

    $GOCO
    Financials

    Live finance-specific insights

    See more
    • GoHealth Reports First Quarter 2025 Results

      CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO) ("GoHealth" or the "Company"), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three months ended March 31, 2025. First Quarter Highlights First quarter 2025 net revenues of $221.0 million, a 19.1% increase compared to $185.6 million in the prior year period.First quarter 2025 net loss of $9.8 million, a 54.2% improvement compared to a net loss of $21.3 million in the prior year period.First quarter 2025 Adjusted EBITDA1 of $42.1 million, a 56.4% increase compared to $26.9 million in the prior year period.First quarter 2025 Submissions2 were

      5/13/25 7:00:00 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth to Announce First Quarter 2025 Results on May 13, 2025

      CHICAGO, May 05, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its first quarter 2025 financial results on the morning of May 13, 2025. Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Brendan Shanahan, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results. A live audio webcast of the conference call will be available via GoHealth's Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand listening

      5/5/25 9:00:00 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth Reports Strong Fourth Quarter and Fiscal Year 2024 Results, Driven by a Successful Annual Enrollment Period

      CHICAGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO) ("GoHealth" or the "Company"), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three and twelve months ended December 31, 2024. Fourth Quarter Highlights Achieved net revenues of $389.1 million, a substantial 41% increase compared to the prior year period. Submissions grew to 481,445, representing a 67% increase compared to the prior year period. Net income of $58.0 million, a substantial improvement of $60.3 million compared to the prior year period. Adjusted EBITDA1 surged to $117.8 million, a significant 107% increase compared to the

      2/27/25 7:00:36 AM ET
      $GOCO
      Specialty Insurers
      Finance

    $GOCO
    Leadership Updates

    Live Leadership Updates

    See more

    $GOCO
    SEC Filings

    See more

    $GOCO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Brendan Shanahan Appointed Chief Financial Officer of GoHealth, Bringing Decades of Leadership in Healthcare and Financial Strategy

      CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, today announced the appointment of Brendan Shanahan as Chief Financial Officer (CFO), effective October 14, following a comprehensive search process. Mr. Shanahan, a seasoned executive with over 30 years of financial leadership experience and over 20 years of expertise in the Medicare Advantage space, will oversee GoHealth's financial strategy and operations, contributing to the company's profitable growth and innovation efforts. "Brendan's extensive expertise in financial strategy, M&A, operational leadership, and deep knowledge of t

      10/10/24 9:00:00 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth Appoints Vance Johnston as Chief Financial Officer

      CHICAGO, Dec. 6, 2021 /PRNewswire/ -- GoHealth, Inc. (GoHealth) (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced today that Vance Johnston will join the Company as Chief Financial Officer (CFO) on December 7, 2021.  As previously announced, Travis Matthiesen, the Company's current CFO, will transition to the role of Chief Transformation Officer and will work closely with Johnston to ensure a smooth transition. "We are very pleased that Vance will be joining the GoHealth executive team as CFO," said Clint Jones, co-fou

      12/6/21 4:05:00 PM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth Appoints Dr. Paul Hain, M.D. as Chief Medical Officer

      CHICAGO, Dec. 1, 2020 /PRNewswire/ -- GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace, announced today that Dr. Paul Hain, M.D. has joined the company as Chief Medical Officer. In this newly created role, Dr. Hain will work side-by-side with GoHealth's growing TeleCare team, directly building clinical functions within the recently developed Encompass Platform, a digital health solution that provides strategic value to GoHealth members and enterprise partners. Dr. Hain will focus on key member touchpoints including care management and navigation, provider and value-based care engagement, pharmacy engagement, health risk assessments, social determinant of he

      12/1/20 8:06:00 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • SEC Form NT 10-Q filed by GoHealth Inc.

      NT 10-Q - GoHealth, Inc. (0001808220) (Filer)

      5/16/25 5:02:44 PM ET
      $GOCO
      Specialty Insurers
      Finance
    • SEC Form 10-Q filed by GoHealth Inc.

      10-Q - GoHealth, Inc. (0001808220) (Filer)

      5/16/25 5:01:07 PM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - GoHealth, Inc. (0001808220) (Filer)

      5/13/25 7:04:07 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth Reports First Quarter 2025 Results

      CHICAGO, May 13, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (NASDAQ:GOCO) ("GoHealth" or the "Company"), a leading health insurance marketplace and Medicare-focused digital health company, today announced financial results for the three months ended March 31, 2025. First Quarter Highlights First quarter 2025 net revenues of $221.0 million, a 19.1% increase compared to $185.6 million in the prior year period.First quarter 2025 net loss of $9.8 million, a 54.2% improvement compared to a net loss of $21.3 million in the prior year period.First quarter 2025 Adjusted EBITDA1 of $42.1 million, a 56.4% increase compared to $26.9 million in the prior year period.First quarter 2025 Submissions2 were

      5/13/25 7:00:00 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth's Statement on Recent Allegations in the United States False Claims Act Complaint

      CHICAGO, May 07, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, firmly denies the allegations made by the Government in a lawsuit in which the company has been named as a defendant related to events that allegedly occurred between 2016 and 2021. We are disappointed that the Government is pursuing claims against a company that has at all times worked to advance the interests of the Medicare Advantage program and the Medicare beneficiaries it serves. GoHealth maintains that it complied with the laws that were specifically designed by Congress and HHS to address payments by Medicare Advanta

      5/7/25 8:00:00 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • GoHealth to Announce First Quarter 2025 Results on May 13, 2025

      CHICAGO, May 05, 2025 (GLOBE NEWSWIRE) -- GoHealth, Inc. (GoHealth) (NASDAQ:GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its first quarter 2025 financial results on the morning of May 13, 2025. Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Brendan Shanahan, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results. A live audio webcast of the conference call will be available via GoHealth's Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand listening

      5/5/25 9:00:00 AM ET
      $GOCO
      Specialty Insurers
      Finance

    $GOCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by GoHealth Inc. (Amendment)

      SC 13D/A - GoHealth, Inc. (0001808220) (Subject)

      8/25/23 6:15:20 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • SEC Form SC 13D/A filed by GoHealth Inc. (Amendment)

      SC 13D/A - GoHealth, Inc. (0001808220) (Subject)

      8/25/23 6:03:57 AM ET
      $GOCO
      Specialty Insurers
      Finance
    • SEC Form SC 13D/A filed by GoHealth Inc. (Amendment)

      SC 13D/A - GoHealth, Inc. (0001808220) (Subject)

      5/19/23 6:08:49 AM ET
      $GOCO
      Specialty Insurers
      Finance

    $GOCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Kotte Vijay bought $100,275 worth of shares (7,500 units at $13.37), increasing direct ownership by 1% to 653,630 units (SEC Form 4)

      4 - GoHealth, Inc. (0001808220) (Issuer)

      11/15/23 10:10:34 AM ET
      $GOCO
      Specialty Insurers
      Finance